IMR Press / EJGO / Volume 25 / Issue 6 / pii/2004270

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Ulcerative locally advanced breast cancer: the efficacy of combined anthracycline-based and hormonal therapy

Show Less
1 Department of Surgery, Department of Histology- Embryology, Democritus University of Thrace, Alexandroupolis (Greece)
2 Department of Oncology, Department of Histology- Embryology, Democritus University of Thrace, Alexandroupolis (Greece)
3 Thraki Medical Center, Department of Histology- Embryology, Democritus University of Thrace, Alexandroupolis (Greece)
4 Department of Pathology, Drama Hospital, Greece
Eur. J. Gynaecol. Oncol. 2004, 25(6), 716–718;
Published: 10 December 2004

Aim: In the literature there are numerous large prospective studies on patients with locally advanced breast cancer, however little is reported on the management of ulcerative breast cancer. The aim of this study was to evaluate the employment of combined anthra­cycline-based chemotherapy and hormonal therapy in ulcerative locally advanced mammary carcinoma. Patients and methods: Four patients, aged from 67 to 83 years, presented with ulcerative breast cancer resulting in breast destruc­tion. Histological examination of biopsy specimens revealed highly differentiated estrogen receptor-positive ductal carcinomas. All tumours were classified as locally advanced since there was no clinical or radiologic evidence of distant metastasis in any of the patients. Due to their religious beliefs all patients refused any other treatment but chemotherapy. In these patients hemostasis and reduction of bacterial overgrowth were followed by administration of anthracycline-based chemotherapy and hormonal therapy. Results: All patients responded well; ulcer healing and partial remission were achieved for a period ranging from 19 to 28 months before disease progression. Conclusion: There is clinical evidence from this study that the combination of anthracycline-based palliative chemotherapy coupled with tamoxifen is beneficial for patients with inoperable ulcerative breast cancer.

Locally advanced breast cancer
Ulcerative breast cancer
Silver-charcoal dressings
Back to top